Kronos Bio Reports First-Quarter 2024 Financial Results
09 mai 2024 16h05 HE
|
Kronos Bio, Inc.
— $152.0 million cash runway into the second half of 2026 — — A study update on KB-0742-1001 will be presented at the upcoming American Society of Clinical Oncology (ASCO); expansion cohorts at new...
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24 avr. 2024 16h01 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
21 mars 2024 07h05 HE
|
Kronos Bio, Inc.
Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half...
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
07 mars 2024 16h05 HE
|
Kronos Bio, Inc.
Company to assess KB-0742 at planned new dose schedule in ongoing phase 1/2 study; topline data from expansion cohort at new dose schedule expected in the first half of 2025 IND-enabling studies for...
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
05 mars 2024 16h44 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
27 févr. 2024 16h05 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
25 janv. 2024 08h00 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif., and CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
18 déc. 2023 16h06 HE
|
Kronos Bio, Inc.
Phase 1b portion of phase 1b/2 lanraplenib study in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia completed; review of data does not support continuing to phase 2 New...
Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
04 déc. 2023 08h00 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference
27 nov. 2023 16h05 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...